A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Pelareorep (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 According to an Oncolytics Biotech media release, results will be discussed in a conference call for Analysts and Institutional Investors on Wednesday, February 7, 2018 at 8:30 a.m. ET.
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History